Véniant, Murielle M.

Acute glucose-lowering and insulin-sensitizing action of FGF21 in insulin-resistant mouse models—association with liver and adipose tissue effects

Xu, J., Stanislaus, S., Chinookoswong, N., Lau, Y. Y., Hager, T., Patel, J., Ge, H., Weiszmann, J., Lu, S.-C., Graham, M., et al. (2009) · American Journal of Physiology-Endocrinology and Metabolism

Fibroblast Growth Factor ResearchPancreatic function and diabetes

Cited by 340

Anti-obesity effects of GIPR antagonists alone and in combination with GLP-1R agonists in preclinical models

Killion, E. A., Wang, J., Yie, J., Shi, S. D.-H., Bates, D., Min, X., Komorowski, R., Hager, T., Deng, L., Atangan, L., et al. (2018) · Science Translational Medicine

Regulation of Appetite and ObesityPharmacology and Obesity Treatment

Cited by 237

Long-acting MIC-1/GDF15 molecules to treat obesity: Evidence from mice to monkeys

Xiong, Y., Walker, K., Min, X., Hale, C., Tran, T., Komorowski, R., Yang, J., Davda, J., Nuanmanee, N., Kemp, D., et al. (2017) · Science Translational Medicine

GDF15 and Related BiomarkersRegulation of Appetite and Obesity

Cited by 236

A GIPR antagonist conjugated to GLP-1 analogues promotes weight loss with improved metabolic parameters in preclinical and phase 1 settings

Véniant, M. M., Lu, S.-C., Atangan, L., Komorowski, R., Stanislaus, S., Cheng, Y., Wu, B., Falsey, J. R., Hager, T., Thomas, V. A., et al. (2024) · Nature Metabolism

Pharmacology and Obesity TreatmentRegulation of Appetite and Obesity

Cited by 218

Treating Diabetes and Obesity with an FGF21-Mimetic Antibody Activating the βKlotho/FGFR1c Receptor Complex

Foltz, I. N., Hu, S., King, C., Wu, X., Yang, C., Wang, W., Weiszmann, J., Stevens, J., Chen, J. S., Nuanmanee, N., et al. (2012) · Science Translational Medicine

Fibroblast Growth Factor ResearchAdipokines, Inflammation, and Metabolic Diseases

Cited by 211

Pharmacologic Effects of FGF21 Are Independent of the “Browning” of White Adipose Tissue

Véniant, M. M., Sivits, G., Helmering, J., Komorowski, R., Lee, J., Fan, W., Moyer, C., & Lloyd, D. J. (2015) · Cell Metabolism

Fibroblast Growth Factor ResearchAdipose Tissue and Metabolism

Cited by 204

Lack of Overt FGF21 Resistance in Two Mouse Models of Obesity and Insulin Resistance

Hale, C., Chen, M. M., Stanislaus, S., Chinookoswong, N., Hager, T., Wang, M., Véniant, M. M., & Xu, J. (2012) · Endocrinology

Fibroblast Growth Factor ResearchAdipokines, Inflammation, and Metabolic Diseases

Cited by 185

Chronic glucose-dependent insulinotropic polypeptide receptor (GIPR) agonism desensitizes adipocyte GIPR activity mimicking functional GIPR antagonism

Killion, E. A., Chen, M., Falsey, J. R., Sivits, G., Hager, T., Atangan, L., Helmering, J., Lee, J., Li, H., Wu, B., et al. (2020) · Nature Communications

Regulation of Appetite and ObesityAdipokines, Inflammation, and Metabolic Diseases

Cited by 151

FGF21 N‐ and C‐termini play different roles in receptor interaction and activation

Yie, J., Hecht, R., Patel, J., Stevens, J., Wang, W., Hawkins, N., Steavenson, S., Smith, S., Winters, D., Fisher, S., et al. (2009) · FEBS Letters

Fibroblast Growth Factor ResearchParathyroid Disorders and Treatments

Cited by 149

FGF21 Promotes Metabolic Homeostasis via White Adipose and Leptin in Mice

Véniant, M. M., Hale, C., Helmering, J., Chen, M. M., Stanislaus, S., Busby, J., Vonderfecht, S., Xu, J., & Lloyd, D. J. (2012) · PLoS ONE

Fibroblast Growth Factor ResearchAdipokines, Inflammation, and Metabolic Diseases

Cited by 141

Susceptibility to atherosclerosis in mice expressing exclusively apolipoprotein B48 or apolipoprotein B100.

Véniant, M. M., Pierotti, V, Newland, D., Cham, C. M., Sanan, D. A., Walzem, R. L., & Young, S. G. (1997) · Journal of Clinical Investigation

Cholesterol and Lipid MetabolismAtherosclerosis and Cardiovascular Diseases

Cited by 100

Understanding the Physical Interactions in the FGF21/FGFR/β‐Klotho Complex: Structural Requirements and Implications in FGF21 Signaling

Yie, J., Wang, W., Deng, L., Tam, L., Stevens, J., Chen, M. M., Li, Y., Xu, J., Lindberg, R., Hecht, R., et al. (2012) · Chemical Biology & Drug Design

Fibroblast Growth Factor ResearchParathyroid Disorders and Treatments

Cited by 99

Glucose-dependent insulinotropic polypeptide receptor therapies for the treatment of obesity, do agonists=antagonists?

Killion, E. A., Lu, S.-C., Fort, M., Yamada, Y., Véniant, M. M., & Lloyd, D. J. (2020) · Endocrine Reviews

Regulation of Appetite and ObesityPharmacology and Obesity Treatment

Cited by 94

GIPR antagonist antibodies conjugated to GLP-1 peptide are bispecific molecules that decrease weight in obese mice and monkeys

Lu, S.-C., Chen, M., Atangan, L., Killion, E. A., Komorowski, R., Cheng, Y., Netirojjanakul, C., Falsey, J. R., Stolina, M., Dwyer, D., et al. (2021) · Cell Reports Medicine

Regulation of Appetite and ObesityDiabetes Treatment and Management

Cited by 91

FGF21 Is Not a Major Mediator for Bone Homeostasis or Metabolic Actions of PPARα and PPARγ Agonists

Li, X., Stanislaus, S., Asuncion, F., Niu, Q.-T., Chinookoswong, N., Villasenor, K., Wang, J., Wong, P., Boyce, R., Dwyer, D., et al. (2017) · Journal of Bone and Mineral Research

Fibroblast Growth Factor ResearchBone Metabolism and Diseases

Cited by 61

Haploinsufficiency of the Insulin Receptor in the Presence of a Splice-Site Mutation in Ppp2r2a Results in a Novel Digenic Mouse Model of Type 2 Diabetes

Goldsworthy, M., Bai, Y., Li, C.-M., Ge, H., Lamas, E., Hilton, H., Esapa, C. T., Baker, D., Baron, W., Juan, T., et al. (2016) · Diabetes

Metabolism, Diabetes, and CancerPancreatic function and diabetes

Cited by 35

A Phase 1, Randomized, Double-Blind, Placebo-Controlled Single and MultipleAscending Dose Study of AMG 133 in Subjects with Obesity

Strande, J. L., Kurra, V., Jeswani, R., Oberoi, R., Sharpsten, L., Neutel, J., Véniant, M. M., & Parnes, J. R. (2023) · Metabolism

Pharmacology and Obesity TreatmentDiabetes Treatment and Management

Cited by 7